A biotech company has made a significant development in treating gastrointestinal stromal tumors, a rare type of stomach cancer. The development has shown unprecedented efficacy and may be a first in 20 years, potentially clearing the path for FDA approval. The treatment targets treatment-resistant tumors, although the use of certain therapies, such as tyrosine kinase inhibitors, can have adverse effects.